Back to Trial

Oracle Runs

Oracle findings and outcome history for Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE) (NCT05925530).

Runs
4
Findings
4
Latest Run
Apr 6, 2026, 2:08 PM
Resolution Evidence
Outcome
YES
Status
Resolved
Settlement Date
4/6/26 UTC
Executive Summary

Interim analysis (ESMO 2025) of this exact Phase 2 trial reports primary endpoint resection rate 85.7% (high R0 94.4%, pCR 27.6%). Sources explicitly frame as 'impressive', 'encouraging safety', outcomes 'consistent with AEGEAN'. Primary endpoint clearly met with positive interpretation for this trial.

Sources
Web Searchannalsofoncology.org1/1/25
Interim analysis (IA) of the phase II MDT-BRIDGE study

The resection rate was 85.7% (95% CI 76.4–92.4), with 68/72 having R0 resections (94.4%). pCR rate 27.6%. Safety generally consistent with prior studies. Outcomes consistent with AEGEAN.

View source
Web Searchoncodaily.com10/18/25
Stephen V Liu: Impressive Results from MDT-BRIDGE at ESMO25

Impressive results from MDT-BRIDGE at ESMO25. ... 82% of borderline-resectable cases became resectable.

View source
Web Searchlinkedin.com10/21/25
MDT-BRIDGE trial results on durvalumab + chemotherapy in NSCLC

Early results show: 86% surgical resection rate overall, 94% R0 resection rate, 28% pCR in resected patients, encouraging safety profile.

View source
All Oracle Findings

Every stored oracle finding for this trial, including pending, dismissed, rejected, superseded, and accepted items.

YESAccepted85% confidenceGrok 4.20 (xAI)

Will the results be positive?

Interim analysis (ESMO 2025) of this exact Phase 2 trial reports primary endpoint resection rate 85.7% (high R0 94.4%, pCR 27.6%). Sources explicitly frame as 'impressive', 'encouraging safety', outcomes 'consistent with AEGEAN'. Primary endpoint clearly met with positive interpretation for this trial.

Found Apr 6, 2026, 2:08 PMOutcome date Oct 1, 2025, 12:00 AMReviewed Apr 6, 2026, 2:26 PM
Web Searchannalsofoncology.orgJan 1, 2025, 12:00 AM
Interim analysis (IA) of the phase II MDT-BRIDGE study
The resection rate was 85.7% (95% CI 76.4–92.4), with 68/72 having R0 resections (94.4%). pCR rate 27.6%. Safety generally consistent with prior studies. Outcomes consistent with AEGEAN.
Web Searchoncodaily.comOct 18, 2025, 12:00 AM
Stephen V Liu: Impressive Results from MDT-BRIDGE at ESMO25
Impressive results from MDT-BRIDGE at ESMO25. ... 82% of borderline-resectable cases became resectable.
Web Searchlinkedin.comOct 21, 2025, 12:00 AM
MDT-BRIDGE trial results on durvalumab + chemotherapy in NSCLC
Early results show: 86% surgical resection rate overall, 94% R0 resection rate, 28% pCR in resected patients, encouraging safety profile.
NO_DECISIONDismissed90% confidencemanual-chat-review

Will the results be positive?

ClinicalTrials.gov still lists this study as active not recruiting with no posted results, so there is not yet a clear public positive or negative trial readout.

Found Apr 4, 2026, 8:54 PMReviewed Apr 4, 2026, 10:33 PM
ClinicalTrialsclinicaltrials.govJan 29, 2026, 12:00 AM
Study Details | NCT05925530 | ClinicalTrials.gov
ClinicalTrials.gov lists active not recruiting; primary completion 2026-01-12; hasResults=false on the latest posted update.
NO_DECISIONDismissed88% confidenceGPT-5.4 (OpenAI)

Will the results be positive?

A public interim readout exists, but the cited trial-specific evidence is still ambiguous. The ESMO 2025 abstract reports promising interim numbers, yet does not clearly say MDT-BRIDGE met its primary endpoint or deliver a definitive positive/negative framing. AstraZeneca’s trial-summary page also says no results documents are posted yet.

Found Apr 3, 2026, 4:02 PMReviewed Apr 3, 2026, 4:47 PM
Web Searchs3.eu-central-1.amazonaws.com
LBA65: Neoadjuvant durvalumab + chemotherapy in resectable or borderline resectable stage IIB-IIIB NSCLC: Interim analysis of phase 2 MDT-BRIDGE
Interim analysis: 95.2% received surgery or CRT; resection rate 85.7%; pCR 27.6%. Conclusion says MDT follow-up ‘could allow more patients to receive local treatment’ and compares outcomes with AEGEAN, but does not clearly state the trial met its primary endpoint.
Sponsorastrazeneca.trialsummaries.com
TrialSummaries.com - MDT-BRIDGE study details
AstraZeneca’s trial summary page lists primary completion in January 2026 and states: ‘No documents have been posted yet.’
NO_DECISIONDismissed84% confidenceGPT-5.4 (OpenAI)

Will the results be positive?

Only an interim public readout was found. Non-official conference/commentary sources describe MDT-BRIDGE as encouraging/promising, but AstraZeneca’s trial-summary page shows no posted results document. Because the evidence is interim and incomplete rather than a clear final trial-specific sponsor readout, this is best classified as no_decision.

Found Apr 1, 2026, 6:35 PMReviewed Apr 1, 2026, 6:36 PM
Sponsorastrazeneca.trialsummaries.com
TrialSummaries.com - Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D
Sponsor-authorized trial summary page for NCT05925530 says: 'No documents have been posted yet,' indicating no formal results summary was publicly posted there.
Web Searchtribemd.comOct 27, 2025, 12:00 AM
Estudo MDT-BRIDGE aponta avanços no manejo de NSCLC localmente avançado
Conference coverage of the exact Phase 2 MDT-BRIDGE interim analysis says the study 'reinforces a promising concept' and reports high resection/R0 rates with tolerable safety, but notes longer follow-up is needed.
Web Searchlinkedin.com
ESMO Berlin: MDT-BRIDGE trial results on durvalumab + chemo in NSCLC
Post summarizing the interim analysis calls the MDT-BRIDGE results 'very encouraging' and 'promising,' with ~86% resection, 94% R0 resection, and ~28% pCR, but it is a third-party conference summary rather than an official final readout.
Outcome History

Public history of accepted oracle reviews and recorded outcome changes for this trial.

Accepted Oracle ReviewApr 6, 2026, 2:26 PM

Will the results be positive?

PendingtoYEScurrentYES
Grok 4.20 (xAI)85% confidenceReviewed Apr 6, 2026, 2:26 PM

Interim analysis (ESMO 2025) of this exact Phase 2 trial reports primary endpoint resection rate 85.7% (high R0 94.4%, pCR 27.6%). Sources explicitly frame as 'impressive', 'encouraging safety', outcomes 'consistent with AEGEAN'. Primary endpoint clearly met with positive interpretation for this trial.